Weight Loss Treatment for COVID-19 in Patients with NCDs: A Pilot Prospective Clinical Trial
Practical Solutions and Value Highlights
The study evaluated the effects of a restricted diet on inflammation, metabolic profile, and body composition in COVID-19 patients with noncommunicable chronic diseases (NCDs). This included type 2 diabetes (T2D), hypertension, or nonalcoholic steatohepatitis (NASH).
Interventions involved a restricted diet with calorie restriction, hot water drinking, walking, and sexual self-restraint.
Key Findings
In the main group, patients with overweight experienced a significant weight loss. Body temperature and C-reactive protein decreased significantly compared to the control group. There were also favorable impacts on blood pressure, glucose/lipid metabolism, liver function, and chest CT results in the main group at 14 days of treatment.
Value of the Treatment
The rapid weight loss treatment showed potential benefits for COVID-19 patients with comorbid NCDs over traditional medical treatment, as it improved clinical and laboratory data, allowed patients to discontinue previous medications, and positively impacted various health parameters.
Importance of Clinical Trials
Clinical trials are crucial for developing safe and effective treatments and should be integrated into everyday medical practice.
Find out more about how DocSym, our AI-driven platform, consolidates clinical knowledge and standards, and how our mobile apps support healthcare operations and patient care at aidevmd.com.
